ライフサイエンスコーパス: coagulation factor IX

1 an adenoviral vector expressing human blood coagulation factor IX.

2 xicity and promote the delivery of the human coagulation factor IX and alpha-galactosidase genes into

3 n with functional outcome; and two proteins (coagulation factor IX and complement C5) positively asso

4 We demonstrated that coagulation factor IX and complement component C4-bindin

5 in patients with haemophilia B (defective in coagulation factor IX) and the Marfan syndrome (defectiv

6 is caused by the absence of functional blood coagulation factor IX, and is an excellent candidate for

7 gene on the X chromosome that encodes blood coagulation factor IX, and is predicted to alter RNA spl

8 o demonstrate a polymorphism of human plasma coagulation factor IX antigen in double antibody solid-p

9 g-term expression (>5 months) of human blood coagulation factor IX at levels that were therapeutic in

10 Coagulation factor IX deficiency causes hemophilia B in

11 products for the treatment of hemophilia B (coagulation factor IX deficiency) and one for hemophilia

12 We have used gene targeting to develop a coagulation factor IX-deficient (factor IX-knockout) mou

13 lia B is caused by the absence of functional coagulation factor IX (F.IX) and represents an important

14 sociated viral (AAV) vector expressing blood coagulation factor IX (F.IX) can result in long-term exp

15 While substantial levels of coagulation factor IX (F.IX) have been achieved using AA

16 coagulopathy caused by absence of functional coagulation factor IX (F.IX).

17 g disorder hemophilia B [deficiency in blood coagulation factor IX (F.IX)] by gene replacement therap

18 In hemophilia B (coagulation factor IX [F.IX] deficiency), lack of endoge

19 at antigenic epitopes derived from an ARF in coagulation factor IX (F9) cDNA can induce CTL reactivit

20 n particular, we target a promoterless human coagulation factor IX (F9) gene to the liver-expressed m

21 a B (HB) replacement therapy is evaluated by coagulation factor IX (FIX) activity in plasma, although

22 d efficient induction of immune tolerance to coagulation factor IX (FIX) by direct intramuscular inje

23 emonstrated induction of immune tolerance to coagulation factor IX (FIX) by hepatic adeno-associated

24 Long-term expression of coagulation factor IX (FIX) has been observed in murine

25 associated viral (AAV) vector encoding blood coagulation factor IX (FIX) into skeletal muscle results

26 d mice with combined deficiencies of Plg and coagulation factor IX (fIX) or XI (fXI) to determine the

27 ion and most importantly the activity of the coagulation factor IX (FIX) produced by mature hepatocyt

28 nced the expression and clotting activity of coagulation factor IX (FIX) to nearly 2-fold that of imm

29 ssion and function, we designed an optimized coagulation factor IX (FIX) variant and used multiple me

30 safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which,

31 A recombinant fusion protein linking coagulation factor IX (FIX) with human albumin (rIX-FP)

32 coagulopathy caused by absence of functional coagulation factor IX (FIX).

33 calin from Rhodnius prolixus that binds with coagulation factors IX (fIX) and IXa (fIXa).

34 haemophilia B (</=2 IU/dL [</=2%] endogenous coagulation factor IX [FIX] activity).

35 onsidering the enzymatic domain of activated coagulation factor IX (FIXa) is homologous to those of t

36 ient to maintain therapeutic levels of human coagulation Factor IX for more than six months in mice u

37 Oral delivery of coagulation factor IX fused with cholera toxin beta-subu

38 are the result of missense mutations in the coagulation factor IX gene and defective circulating fac

39 cin resistance marker gene (neo) and a human coagulation factor IX genomic construct designed for exp

40 ngle Ca2+ binding EGF-like domain from human coagulation factor IX has recently been solved.

41 tion of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associate

42 Plasma human coagulation factor IX (hF.IX) levels in mice originating

43 arried out a systematic study on human blood coagulation factor IX (hFIX) and anti-coagulant protein

44 To determine the most robust human coagulation factor IX (hFIX) expression cassette in an a

45 the liver-specific expression of human blood coagulation factor IX (hFIX).

46 er-specific promoter-1 encoding either human coagulation factors IX (hFIX) or X (hFX) into Macaca fas

47 We investigated long-term human coagulation factor IX (huFIX) expression of a novel vari

48 d expressing a model therapeutic gene, human coagulation Factor IX, in HEK293T cells.

49 Coagulation factor IX plays a central role in hemostasis

50 oxylase, it is not stimulated by human blood coagulation factor IX propeptides.

51 hilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding.

52 closely related fragment, the Gla domain of coagulation factor IX, the structure of which had previo

53 We studied associations of coagulation factors IX through XIII with risk of future